Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating resectable stage II or III esophageal squamous cell carcinoma (ESCC). However, 5-fluorouracil plus cisplatin does not benefit cohorts with clinical stage III ESCC, suggesting the r...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Mitsuro Kanda, Dai Shimizu, Kazushi Miyata, Osamu Maeda, Chie Tanaka, Yoshikuni Inokawa, Norofumi Hattori, Masamichi Hayashi, Masahiko Ando, Yachiyo Kuwatsuka, Kenta Murotani, Goro Nakayama, Masahiko Koike, Yuichi Ando, Tomoki Ebata, Yasuhiro Kodera
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Esophageal cancer
Squamous cell carcinoma
Neoadjuvant chemotherapy
S-1
Clinical trial
Medicine (General)
R5-920
Accès en ligne:https://doaj.org/article/60bd584ed5604ef4b37d38428dccd043
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/60bd584ed5604ef4b37d38428dccd043

Documents similaires